Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target

Expert Opin Ther Targets. 2008 Oct;12(10):1275-87. doi: 10.1517/14728222.12.10.1275.

Abstract

Background: Raf kinase inhibitory protein (RKIP) belongs to the phosphatidylethanolamine binding protein (PEBP) family that is expressed in both prokaryotic and euakaryotic organisms.

Objective: In this review, we discuss the role of RKIP as a modulator of signal transduction, the relationship of RKIP to other members of the PEBP family, and the role of RKIP in human health and disease.

Results/conclusion: In mammals, RKIP regulates activation of MAPK, NF-kappaB and G protein coupled receptors (GPCRs). As a modulator of key signaling pathways, RKIP affects various cellular processes including cell differentiation, the cell cycle, apoptosis and cell migration. Emerging evidence suggests that RKIP is implicated in several human diseases or disorders, among them metastatic tumorigenesis and Alzheimer's disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Apoptosis / physiology
  • Cell Division / physiology
  • Cell Transformation, Neoplastic
  • Genomic Instability / physiology
  • Humans
  • NF-kappa B / metabolism
  • Neoplasm Metastasis
  • Phosphatidylethanolamine Binding Protein / chemistry
  • Phosphatidylethanolamine Binding Protein / drug effects
  • Phosphatidylethanolamine Binding Protein / physiology*
  • Protein Conformation
  • Receptors, G-Protein-Coupled / metabolism
  • Signal Transduction / physiology
  • raf Kinases / metabolism

Substances

  • NF-kappa B
  • PEBP1 protein, human
  • Phosphatidylethanolamine Binding Protein
  • Receptors, G-Protein-Coupled
  • raf Kinases